These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7603186)

  • 1. Brucella antibodies and oral cholera vaccination.
    Begue RE; Guillen A; Meza R
    Lancet; 1995 Jul; 346(8967):115-6. PubMed ID: 7603186
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
    Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
    Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.
    Cash RA; Music SI; Libonati JP; Craig JP; Pierce NF; Hornick RB
    J Infect Dis; 1974 Oct; 130(4):325-33. PubMed ID: 4443613
    [No Abstract]   [Full Text] [Related]  

  • 4. Stimulation of mucosal immunity.
    Lewis DJ; Hayward CM
    Methods Mol Med; 2003; 87():245-54. PubMed ID: 12958460
    [No Abstract]   [Full Text] [Related]  

  • 5. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.
    Jertborn M; Svennerholm AM; Holmgren J
    J Infect Dis; 1988 Feb; 157(2):374-7. PubMed ID: 3335813
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of Vibrio cholerae toxoid on the levels of antibodies of the IgG, IgA and IgM classes in rabbits].
    Aleksandrowicz J; Kudelski Z
    Med Dosw Mikrobiol; 1986; 38(1):15-22. PubMed ID: 3713366
    [No Abstract]   [Full Text] [Related]  

  • 7. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of Vibrio antibody titers during anti-cholera vaccination].
    Dirimci OT; Cinar V
    Turk Hij Tecr Biyol Derg (1961); 1973; 33(2-3):118-28. PubMed ID: 4807572
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers.
    Pitisuttithum P; Migasena S; Suntharasamai P; Supanaranond W; Desakorn V; Prayurahong B
    Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):201-5. PubMed ID: 2609209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
    Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
    J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.
    Glass RI; Svennerholm AM; Khan MR; Huda S; Huq MI; Holmgren J
    J Infect Dis; 1985 Feb; 151(2):236-42. PubMed ID: 3968450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains.
    García Imia L; Oliva Hernández R; Cedré Marrero B; Valmaseda Pérez T; García Sánchez H; Talavera Coronel A; Pérez Quiñoy JL; Sierra González G
    Lab Anim Sci; 1998 Oct; 48(5):538-41. PubMed ID: 10090073
    [No Abstract]   [Full Text] [Related]  

  • 18. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.
    Clemens JD; van Loon F; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; Khan MR; Yunus M; Huda S
    J Infect Dis; 1991 Jun; 163(6):1235-42. PubMed ID: 2037789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans.
    Jertborn M; Nordström I; Kilander A; Czerkinsky C; Holmgren J
    Infect Immun; 2001 Jun; 69(6):4125-8. PubMed ID: 11349086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antibody response to an oral Ty21a-based typhoid-cholera hybrid is unaffected by prior oral vaccination with Ty21a.
    Dearlove CE; Forrest BD; van den Bosch L; La Brooy JT
    J Infect Dis; 1992 Jan; 165(1):182-3. PubMed ID: 1727891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.